Immuneed, a Swedish life science biotech company, today announced the publication of two key scientific publications, supporting both its immuno-service and its immuno-oncology offerings. The articles demonstrate Immuneed’s unique whole blood loop assay, a tool to predict first-infusion reactions of immunotherapeutics, and a novel targeting and adjuvant strategy to improve T cell responses that can be used for cancer vaccines.
By invitation from Dagens Medicin Agenda Justyna Leja-Jarblad, Service Manager and Business Development at Immuneed held a pitch at Life Science Dagen on December 5.
Meet us at Nordic Life Science Days in Malmö September 12-14. During the conference, Justyna Leja-Jarblad, Laboratory Manager will give a pitch about our Immuno-Oncology project, at the Start Up Challenge on September 12 at 18:30. We are open to partnering meetings throughout the conference. Come and talk to us about our Immuno-Service, Immuno-Oncology, potential collaboration, or anything that interests you!
Immuneed has secured SEK 9M in an oversubscribed financing round. The funding will support the pre-clinical work of our Immuno-Oncology cancer vaccine and be used to increase marketing of the companys analysis service. The new funding secures financing of our pre-clinical program for the cancer vaccine and further engagement for contract manufacturing.